Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.
Fiscal year to December 2025, from the company's annual filing with the SEC.
| Salesyearly sales | $40.5M |
| Sales growthchange from the year before | +25.4% |
| Operating marginshare of sales left after running the business | -394.9% |
| Net marginshare of sales kept as profit | -395.0% |
| Free-cash-flow marginspare cash generated per $100 of sales | -409.3% |
| Return on invested capitalprofit made on each $100 put into the business | -147.2% |
| Return on equityprofit vs. shareholders' accounting value | -586.6% |
| Debt / equitydebt vs. shareholders' accounting value | 2.15 |
| Interest coverhow many times profit covers interest payments | -25.9x |
| Change in share countnegative = the company is buying back its shares | +7.8% |
2 insiders sold $15K (all under pre-arranged plans) on the open market.
| Parison AmySVP, Chief Financial Officer | Sold (plan)Aug 3 | 678 shat $2.58 · $2K |
| Burkly LindaEvp, Chief Scientific Officer | Sold (plan)Jul 28 | 4,928 shat $2.67 · $13K |
From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.
Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy